Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Lessons From Lockdown: Viral Hepatitis Testing and Treatment in the COVID-19 Era
  • CME
  • CE

Credits Available
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: March 14, 2022 Expiration: March 13, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grants provided by:
AbbVie
Gilead Sciences, Inc.
Jordan J. Feld, MD, MPH
Nancy Reau, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Develop strategies to increase viral hepatitis services that may have diminished during the introduction of the COVID-19 pandemic

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Jordan J. Feld, MD, MPH

Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada

Jordan J. Feld, MD, MPH, has disclosed that he has received consulting fees from AbbVie, Arbutus, Antios, Eiger, Enanta, Gilead Sciences, GlaxoSmithKline, and Janssen and funds for research support from AbbVie, Alexion, Deep Genomics, Gilead Sciences, Eiger, Enanta, Finch, Janssen, and Wako/Fujifilm.
Nancy Reau, MD

Professor of Medicine
Chief,
Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Nancy Reau, MD, has disclosed that she has received consulting fees from AbbVie, Arbutus, Antios, Gilead Sciences, Intercept and Salix and funds for research support from AbbVie, Eiger, and Gilead Sciences.

Staff

Jennifer Swanson, PharmD

Editorial Contributor

Jennifer Swanson, PharmD, has no relevant conflicts of interest to report.
Julie Skowronski, NP
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for patients with viral hepatitis.

Goal

The goal of this activity is to enable learners to adapt their patient care strategies to continue to provide high-quality care for patients with viral hepatitis despite the impact of the COVID-19 pandemic.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.50 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.50 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-077-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.50 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 14, 2022, through March 13, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Lessons From Lockdown: Viral Hepatitis Testing and Treatment in the COVID-19 Era
  • CME
  • CE

Loading...
In this engaging dialogue, 2 expert hepatologists discuss strategies for improving linkage to care of patients with viral hepatitis despite the challenges posed by the COVID-19 pandemic.
Jordan J. Feld, MD, MPH
Nancy Reau, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: March 14, 2022 Expiration: March 13, 2023

Related Content

Dr Stefan Zeuzem discusses his take on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Stefan Zeuzem, MD Released: December 5, 2022

Dr Nancy Reau discusses her take on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Nancy Reau, MD Released: December 2, 2022

Prof George Lau: proactive monitoring and treatment are necessary for all patients with CHB, regardless of age, from Clinical Care Options (CCO)

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Released: December 1, 2022

Expert summaries of AASLD, EASL, APASL guidance on monitoring and treating chronic hepatitis B and delta infections, with Maria Buti, Paul Kwo, Grace Wong

Maria Buti, MD Paul Y. Kwo, MD Grace LH Wong, MD Released: December 1, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grants provided by:
AbbVie
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings